Sitemap - Biologic Meds

Posts

Biologics for Moderate to Severe Asthma (November 6, 2024)
Starting a Biologic Prescription (November 5, 2024)
Type 2 Inflammatory Medical Conditions (October 30, 2024)
The Real Cost of Biologic Drugs (October 12, 2024)

Pages

Sitemap (October 13, 2024)
Articles (September 10, 2024)
Accessibility Statement (October 10, 2022)
Contact Us (October 10, 2022)
Resources (October 10, 2022)
- Biologics at Home (October 10, 2022)
- Ask Your Doctor (October 10, 2022)
- Glossary of Terms (October 10, 2022)
Biologics vs Biosimilars (October 10, 2022)
Approved Biologics (October 10, 2022)
- Dupixent (October 11, 2024)
- Cinqair (October 11, 2024)
- Nucala (October 11, 2024)
- Tezpire (October 11, 2024)
- Adbry (October 11, 2024)
- Xolair (October 11, 2024)
- Fasenra (October 11, 2024)
Biologics Myths vs Facts (October 10, 2022)
FAQs About Biologics (October 10, 2022)
Privacy Policy (October 10, 2022)
Biologic Medications (July 11, 2022)

This website was developed by the American Partnership for Eosinophilic Disorders (APFED) and the Allergy & Asthma Network (AAN).

Founded in 2001 by parents of children living with eosinophil-associated diseases, the American Partnership for Eosinophilic Disorders (APFED) is a 501(c)(3) nonprofit organization. APFED assists and supports patients and families affected by eosinophil-associated disorders by providing education, creating awareness, supporting research, and promoting advocacy.

Connect with APFED on social media:

Allergy & Asthma Network (AAN) is the leading national organization advocating on behalf of the 50 million Americans with allergies, asthma and related conditions. Founded in 1985, the Network’s mission has remained, “to end needless death & suffering due to asthma, allergies, and related conditions through outreach, education, advocacy, and research.”

Connect with AAN on social media:

Supported by:

Contact Us | Privacy Policy | Accessibility Statement. |. Sitemap